NEW SENSOR TECHNOLOGY
Avails Medical is advancing the current diagnostics market with a proprietary platform that transforms biochemical reactions into electrical signals.
Avails Medical is advancing the current diagnostics market with a proprietary platform that transforms biochemical reactions into electrical signals.
The Avails digital sensor technology is being developed to streamline the legacy laboratory in-vitro diagnostic process in one device.
Our intuitive, easy-to use device is being developed to provide a digital read-out of microorganism metabolism, enabling real-time pathogen quantification and AST in human specimens.
Avails’ eQuant system delivers your organism specific 0.5 McFarland directly from a positive blood culture (PBC) in an average of one hour, enabling initiation of any antibiotic susceptibility testing (AST) within hours of blood culture positivity.
Product in development. Specifications subject to change.
eQuant is based on a compact single module instrument which holds a cuvette integrated with an electrical sensor and is inoculated with a diluted sample of positive blood culture. Changes in metabolic byproducts of micro-organisms are then monitored in real-time, providing precise organism specific 0.5 McFarland suspensions compatible with conventional AST methods including disk diffusion.
eQuant is being developed to preserve precious bench top real estate in the clinical laboratory, allowing the use of single or multiple units for handling all positive blood cultures in small or large microbiology labs. eQuant’s unique features include:
eQuant is being developed to optimize simple sample preparation with minimal hands-on time, for seamless integration into the laboratory workflow.
Avails’ novel patented electrical sensors will respond to small metabolic byproducts produced by microorganisms for growth detection, and precise pathogen quantification.